Mirikizumab for children with active Crohn’s disease
Treatments studied
Part of Digestive system clinical trials.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has Crohn’s disease (including fistulizing Crohn’s) confirmed by doctors using past exams and biopsy results
- Crohn’s is currently moderately to severely active, based on a pediatric Crohn’s activity score of 30 or higher
- Within 1 month of starting the study, endoscopy shows active disease (using a scoring system like SES-CD)
- Your child has tried at least one Crohn’s medicine before and had not enough benefit, or lost benefit, or had side effects (including steroids, immunomodulators, biologics, or JAK inhibitors)
- Your child does not have certain Crohn’s complications that may need surgery soon, like symptomatic narrowing/strictures, short bowel, or other surgery-planning problems
- Your child does not have a bowel abscess, and has not had bowel surgery in the last 26 weeks or other abdominal surgery in the last 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
This study tests a medication called mirikizumab (an injection) in people over 60 with moderate to severe Crohn's disease or ulcerative colitis. The goal is to see if it effectively reduces inflammation and helps symptoms, while also checking how safe it is for older adults.
This trial is testing whether a drug called mirikizumab, given alongside surgery to repair anal fistulas, can help heal them better in people with Crohn's disease. It aims to provide a new treatment option that may improve healing and quality of life.
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.